Itacitinib
- Generic Name
- Itacitinib
- Drug Type
- Small Molecule
- Chemical Formula
- C26H23F4N9O
- CAS Number
- 1334298-90-6
- Unique Ingredient Identifier
- 19J3781LPM
- Background
Itacitinib has been used in trials studying the treatment of Melanoma, Carcinoma, Metastatic Cancer, Endometrial Cancer, and B-cell Malignancies, among others.
Safety of Itacitinib in Combination With Corticosteroids for Treatment of Steroid-Naive Acute Graft-Versus-Host Disease in Japanese Subjects
- Conditions
- Acute Graft-versus-host Disease
- Interventions
- Drug: Corticosteroid
- First Posted Date
- 2018-04-13
- Last Posted Date
- 2020-03-03
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 14
- Registration Number
- NCT03497273
- Locations
- ๐ฏ๐ต
JA-Aichi Anjo Kosei Hospital, Anjo-Shi, Aichi, Japan
๐ฏ๐ตHokkaido University Hospital, Sapporo-shi, Hokkaido, Japan
๐ฏ๐ตKanagawa Cancer Center, Yokohama-shi, Kanagawa-Ken, Japan
Pembrolizumab and Itacitinib (INCB039110) for Non-Small Cell Lung Cancer
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Biological: Pembrolizumab
- First Posted Date
- 2018-02-07
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 23
- Registration Number
- NCT03425006
- Locations
- ๐บ๐ธ
University of Pennsylvania, Philadelphia, Pennsylvania, United States
GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease
- Conditions
- Hematologic Malignancies
- Interventions
- Drug: Calcineurin inhibitor
- First Posted Date
- 2017-10-25
- Last Posted Date
- 2022-05-02
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 84
- Registration Number
- NCT03320642
- Locations
- ๐ฎ๐น
Comitato Di Bioetica Della Fondazione Irccs Policlinico San Matteo, Pavia, Italy
๐ซ๐ทChru de Lille Hopital Claude Huriez, Lille, France
๐บ๐ธLoyola University Medical Center, Maywood, Illinois, United States
INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.
- First Posted Date
- 2017-09-05
- Last Posted Date
- 2023-09-22
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 1
- Registration Number
- NCT03272464
- Locations
- ๐บ๐ธ
Massachusetts General Hospital, Boston, Massachusetts, United States
A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis
- Conditions
- MPN (Myeloproliferative Neoplasms)
- Interventions
- First Posted Date
- 2017-05-09
- Last Posted Date
- 2022-06-16
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 23
- Registration Number
- NCT03144687
- Locations
- ๐บ๐ธ
Texas Oncology - Tyler, Tyler, Texas, United States
๐ฆ๐นParacelsus Medical University Salzburg, Salzburg, Austria
๐บ๐ธUniversity of Michigan Cancer Center, Ann Arbor, Michigan, United States
GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease
- Conditions
- Graft-versus-host Disease (GVHD)
- Interventions
- First Posted Date
- 2017-05-04
- Last Posted Date
- 2021-08-11
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 439
- Registration Number
- NCT03139604
- Locations
- ๐บ๐ธ
University of Southern California, Los Angeles, California, United States
๐บ๐ธUniversity of California, Los Angeles (UCLA) - Medical Center, Los Angeles, California, United States
๐บ๐ธAdvocate Lutheran General Hospital - Oncology Specialists SC, Park Ridge, Illinois, United States
An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer
- First Posted Date
- 2016-09-28
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 59
- Registration Number
- NCT02917993
- Locations
- ๐บ๐ธ
Valley Hospital, 223 N Van Dien Avenue, Ridgewood, New Jersey, United States
๐บ๐ธWest Virginia University Cancer Institute, 1 Medical Center Drive, Morgantown, West Virginia, United States
๐บ๐ธUniversity of Texas -MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas, United States
Relieving Chronic Itch: Oral Medication
- First Posted Date
- 2016-09-21
- Last Posted Date
- 2019-05-13
- Lead Sponsor
- Washington University School of Medicine
- Registration Number
- NCT02909569
A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- First Posted Date
- 2016-05-03
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 33
- Registration Number
- NCT02760485
- Locations
- ๐บ๐ธ
LAC-USC Medical Center/Kenneth Norris Jr Cancer Hospital, Los Angeles, California, United States
๐บ๐ธPacific Shores Medical Group, Long Beach, California, United States
๐บ๐ธMayo Clinic Arizona, Scottsdale, Arizona, United States
Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors
- Conditions
- MMR-deficient TumorsSolid TumorsHead and Neck CancerPancreatic CancerColorectal Cancer (CRC)Lung CancerMelanomaEndometrial CancerBreast CancerRenal Cell Carcinoma (RCC)
- Interventions
- First Posted Date
- 2016-01-06
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 159
- Registration Number
- NCT02646748
- Locations
- ๐บ๐ธ
John Wayne Cancer Institute at Providence Saint John's Health Center, Santa Monica, California, United States
๐บ๐ธGeorgetown University Medical Center Lombardi CCC, Washington, District of Columbia, United States
๐บ๐ธThe Center for Cancer and Blood Disorders (RCCA MD LLC-Maryland Vidision), Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.